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Table 1.0 Collection of autologous stem cells
Chemo-
mobilization
Cytokine
mobilization
p-value
Median CD34 cells/kg
collected (in millions/kg)
14.9 8.37 .009
Median number
of apheresis days (mean)
2
(2.13)
1
(1.76)
.29
Target dose achieved:
Yes
No
13 (81.3%)
3 (18.8%)
34 (91.9%)
3 (10%)
.26
Abstracts / Biol Blood Marrow Transplant 20 (2014) S104eS127 S119median number of apheresis days was 1 (range 1 e 3). In 721
(88.7%) collections one day of apheresis was required to
achieve the minimum number of HPCs. The median apher-
esis volume for day 1 collections was 20 (range 3.6 e 24) L.
The correlation coefﬁcient between the pre-collection pe-
ripheral blood CD34+ cell count and the ﬁnal product CD34+
cell content is 0.69 (p<.001; Figure 1). The TVT estimate was
highly predictive of the ﬁnal product CD34+ count (r¼0.82,
p<.0001; Figure 2). Aminimumof 2 x 106 CD34+ cells/kgwas
collected in 90.4% of collections.
Discussion: Using the correlation between the pre-collec-
tion peripheral blood CD34+ count and the ﬁnal product HPC
content, the TVT formula can accurately determine the blood
volume to process during apheresis collection. This has
resulted in reduced apheresis time, fewer apheresis days, and
less nursing time. Ultimately, the TVT formula has allowed
our program to improve our resource utilization by accu-
rately predicating the required apheresis volume.155
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Background: Autologous stem cell mobilization can be
achieved using chemo-mobilization (CHM) or growth factors
alone (cytokine-mobilization, CTM). Mobilization with peg-
ﬁlgrastim and “just-in-time” plerixafor has been shown to be
a successful strategy. Experience with pegﬁlgrastim and
planned plerixafor is limited. We here describe our experi-
ence using two mobilization strategies with pegﬁlgrastim
plus plerixafor (CTM) or cyclophosphamide, pegﬁlgrastim
plus plerixafor (CHM).
Methods: We retrospectively identiﬁed patients who
received an auto-SCT for a diagnosis of myeloma at TJU be-
tween July 2010 and June 2013. These 53 patients who had
stem cell mobilization using either CHM (16 patients) with
cyclophosphamide (4 grams/m2), pegﬁlgrastim (12 mg) and
plerixafor (0.24 mg/kg once daily until target dose collected
or maximum of 4 days of apheresis), or CTM with pegﬁl-
grastim plus plerixafor (37 patients). Plerixafor was only
administered as an outpatient. We hypothesized that more
patients in the CHM group reached the prescribed total
CD34-positive stem cell collection as compared to the CTM
group. To test this hypothesis we used the two-sample test
on proportions. For the comparison of the median total CD34
cells/kg dose collection and the median number of apheresis
days we used the Wilcoxon rank sum test and the t-test,
respectively.
Results: There was no difference in patient age at transplant,
sex, and myeloma subtype. The median number of prior in-
duction therapies was similar; there was no signiﬁcant dif-
ference in the prior exposure to lenalidomide, however as
expected, bone marrow plasmacytosis was higher in theCHM group (6% vs. 2%). In the CHM group, 41% were hospi-
talized due to complication (typically neutropenic fevers)
and thus only 9 patients (59%) received the planned dose of
plerixafor as compared to 100% in the CTM group. Therewere
no hospitalizations in the CTM group due to toxicity. CHM
was associated with a signiﬁcantly higher median total
CD34+ cell collection (14.9 x 106/kg vs. 8.37 x 106/kg,
p¼0.009) (Table 2). CTM is associated with fewer collection
days (median 1 day vs. 2 days, p¼.29) and more patients
achieving the target CD34+ cell dose of 6.0 x 106/kg (91.9% vs.
81.3%, p¼.26).
Conclusion: The preferred method to mobilize autologous
stem cells should be with pegﬁlgrastim and planned plerix-
afor since it is able to achieve the prescribed cell dose, is
associated with less toxicity and risk of hospitalization. This
analysis suggests that per 100 patients collected a total of 100
days of plasmaphresis could be avoided if all patients were
mobilized with growth factors alone.156
Twenty Years of Autologous Stem Cell Transplantation in
Diffuse Large B-Cell Lymphoma e a Single Center
Experience
Margarida Dantas Brito 1,
Fernando Manuel de Castro Campilho 2, Rosa Branca Ferreira 3,
Carlos Pinho Vaz 4, Susana Roncon 5, Antonio Campos 6.
1 Serviço de Hemato-Oncologia, Instituto Português de
Oncologia do Porto, Porto, Portugal; 2 Bone Marrow Transplant
Unit, Instituto Português de Oncologia PORTO, Porto, Portugal;
3 Bone Marow Transplantation Unit, Instituto Português de
Oncologia do Porto, Porto, Portugal; 4 Bone Marrow
Transplantation Unit, Instituto Português de Oncologia Porto,
Porto, Portugal; 5 Serviço de Terapia Celular, Instituto Português
de Oncologia do Porto, Porto, Portugal; 6 Bone Marrow
Transplantation Unit, Instituto Portugues de Oncologia Centro
do Porto, Porto, Portugal
Background: Patients (pt) with advanced stage and high
International Prognostic Index (IPI) or relapsed/primary re-
fractory diffuse large B-cell lymphoma (DLBCL) have an
adverse prognosis and are frequently consolidated with
autologous stem cell transplantation (SCT).
Aim: Evaluation of a single center experience with SCT in
DLBCL.
Methods: Retrospective analysis of outcome of adult pt
submitted to SCT in DLBCL, between October 1992 and
December 2012. Data were collected from the database and
the medical records.
Results: 152 SCT were performed in various histological
subtypes of DLBCL, during this time period. Statistical anal-
ysis was performed in 113 pt with "classical" DLBCL and
histological variants were excluded.
Median age at SCT was 49 years (16-67), 68 males/45
females. At diagnosis the majority of pt were in advanced
stage (85%) and had an IPI 2 or 3 (47%, 30% respectively).
1 year 3 years 5 years
Group 1 91%(4) 86%(5) 83%(6)
Group 2 86%(9) 86%(9) 86%(9)
Group 3 87%(9) 73%(12) 73%(12)
Group 4 63%(11) 46%(12) 38%(12)
Year Total # of units destroyed
2011 112
2012 35
2013* 127
*Through 10/9/2013
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chemotherapy (CT) we divided the pt in the following
groups: 1) 64 pt in 1st complete remission (CR) after 1 CT
line, all with IPI2; 2) 15 pt in 1st CR after 2 CT lines; 3) 15
pt in 2nd CR; 4) 19 pt with more advanced diseased. Ritux-
imab (R) was used with CT in 78 pt before SCT. The 1st line
CT most frequently used was: R-CHOP: 71 pt (63%); CHOP:
28 pt (25%).
Conditioning regimen was: 93 pt BEAM and 20 pt
FEAM. Hematopoietic stem cells were collected from:
peripheral blood (PB) in 100, bone marrow (BM) in 2, and
PB+BM in 11 pt.
The cause of death was: relapse/progression - 17 pt; non-
relapsed mortality e 8 pt and secondary neoplasia 1pt.
The median follow up of alive pt was 34 months (1-221).
Overall survival (OS) at 1, 3 and 5 years was 85%(3);
75%(4); 73%(5). DFS at 1, 3 and 5 years was 84%(4);
80%(4); 75%(5) respectively.
There were signiﬁcant differences in OS between the 4
groups considered e table 2 (p<0.01). In univariate anal-
ysis OS was signiﬁcantly better if: early stage at diagnosis,
less than 2 CT lines before SCT, disease status before SCT in
CR, ﬁrst line CT with R-CHOP, PB stem cells.
Conclusion: About 70 % of high-risk pt were free of disease
after conventional CT followed by SCT. The outcome is
inﬂuenced by disease status at SCT. Despite our results don’t
allow direct comparison of the impact of immunoCT with R,
our pt in the R group had a better outcome.Most studies with
SCT consolidation in these pt were performed in the pre-R
era. There is as need to redeﬁne the role of this treatment
strategy nowadays. Further knowledge of prognosis factors is
necessary, especially in young pt with high-risk disease at 1st
CR, to determine whether the SCT still improves outcome.BMT ADMINISTRATORS/QUALITY157
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Background/Objective: 126 patients were identiﬁed as be-
ing deceased with over 350 stem cell units in storage. The
inability to dispose of these cells has a signiﬁcant impact on
our program; primarily freezer space availability.
The process of obtaining required documentation for the
disposal of cells had not been streamlined, and no one had
oversight for the process, resulting in a lack of documenta-
tion needed to dispose of cells.
Methods: In June of 2012, a data manager took ownership of
the project. In July of 2012, the Cellular Therapeutics
Department Cell Destruction Policy was revised to include
the SSDI report as valid documentation necessary for
destruction of cells and the new process was implemented.Per programmatic policy, appropriate documentation is
requested as soon as possible after notiﬁcation of a re-
cipient’s death. Aggressive attempts are made to obtain
EITHER:
A death certiﬁcate
OR An SSDI report
If any information is inconsistent, additional corrobo-
rating documentation is still necessary to corroborate patient
identiﬁcation. These documents are scanned and stored on a
(secure) shared drive.
The Cellular Therapeutics (CT) Team then reviews docu-
mentation submitted by the data management team.
Appropriate forms are ﬁlled out by CT and the documenta-
tion is veriﬁed by a second CT Team member. Forms must
then be signed by either the Processing Facility Medical Di-
rector or the recipient’s physician per FACT Guidelines (D
11.1.4). The Product disposal may then occur per policy.
Results: Our freezer capacity is 3660 total units (11 freezers
of different sizes). 2627 Autologous Units and 705 Allogeneic
Units ¼ 3332 total units are currently stored (10/1/
13). With ownership of the new streamlined process,
documentation has been received on an additional 52 pa-
tients (150 units) are now eligible for destruction, and
documentation is pending on an additional 37 patients (104
units). 2013 data represents a 72% increase in cells eligible for
destruction over 2012.158
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Abstract/Background: The prevention of hospital acquired
infections is an ongoing performance improvement oppor-
tunity in our hematopoietic stem cell transplant (HSCT)
population. An outbreak of Vancomycin-Resistant Entero-
cocci (VRE) occurred in late 2011 that extended through
2012. A multidisciplinary approach to impact VRE has
resulted in major improvement and sustained reduction in
VRE rates in 2013.
Objective/Methods:
1. Multidisciplinary Integration
In order to achieve the goal of preventing Hospital
Acquired Infections our program works closely with
the hospital Infection Prevention (IP) team. The IP
team attends/reports unit data and opportunities to:
HSCT Quality Management Meeting (ad hoc)
 Sarah Cannon Blood Cancer Network Infection Pre-
vention Team and Quality Calls
 Both the HSCT and the IP team participate in
monthly IP Multidisciplinary Rounding
 IP performs consultative review of IP speciﬁc HSCT
Policies and Procedures
